Several EGFR-TKIs, including but not limited to erlotinib, gefitinib, afatinib, osimertinib, and icotinib showed efficient therapeutic activities in NSCLC patients harboring EGFR mutations [15,19,20,21,33,41,52,71,73,76,168,169,170,171,172,173]. Here, EGFR is linked to non-small cell lung carcinoma.